Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nelmastobart + docetaxel
- Development stage
- Unknown
- Lead developer
- STCube
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Nelmastobart + docetaxel is a combination therapy being developed by STCube, Inc. for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Nelmastobart is a first-in-class monoclonal antibody and immune checkpoint inhibitor that targets Butyrophilin 1A1 (BTN1A1), a novel immunotherapy target expressed in a significant portion of NSCLC tumors. Docetaxel is a taxane-based chemotherapy that works by stabilizing microtubules, thereby inhibiting cell division. Preclinical evidence suggests that docetaxel upregulates the expression of BTN1A1, potentially sensitizing tumors to nelmastobart, particularly in PD-L1-negative patients. The combination is currently being evaluated in a biomarker-driven Phase 2 clinical trial for patients with BTN1A1-positive (TPS ≥50%) non-squamous NSCLC who have progressed on prior platinum-based chemotherapy or immunotherapy.
- Other names
- Nelmastobart and docetaxel
02
Targets
BTN1A1 (Butyrophilin subfamily 1 member A1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Nelmastobart + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nelmastobart + docetaxel.